The BMMCs, and particularly the positively selected CD34+ cell subpopulation, were assessed for this purpose since the detrimental effects of the free radicals are well-known to induce mutagenesis and malfunction in the bone marrow progenitor cells of MDS patients, which are later released into the peripheral circulation. This evidence concerns the gene CD34 and myelodysplastic syndrome.